(Sharecast News) - Aptamer Group reported solid progress on both the technical and commercial fronts on Friday as it held its annual general meeting.
The AIM-traded firm said that since its recapitalisation in August, it had undergone a cost reduction initiative, streamlining production processes to boost capacity, and decreased material requirements from customers.
It also continued to expand and convert its commercial pipeline, with a recent partnership involving a genetic medicines company to advance Optimer development, facilitating targeted delivery of new medicines.
At 1121 GMT, shares in Aptamer Group were down 2.5% at 1.17p.
Reporting by Josh White for Sharecast.com.


(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.


(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News...


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...


(Sharecast News) - Aptamer Group announced a partnership with Microsaic Systems on Friday, to develop a panel of Optimer binders for integration into ...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:


(Alliance News) - Aptamer Group PLC shares rose on Wednesday, after it said it has signed a GBP465,000 agreement with Timser Group.


(Alliance News) - Aptamer Group PLC on Monday reported progress on all three of its strategic objectives.


(Sharecast News) - Life sciences business Aptamer said on Monday that its current sales pipeline was "strong", with over £3.0m in advanced stage ...


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and Monday and not separate...


(Alliance News) - Aptamer Group PLC on Thursday said it has partnered with Kairos Biotech Ltd for Optimer+ transplant rejection therapies.


(Alliance News) - Aptamer Group PLC on Monday said it filed a patent application aimed at supporting the next stages of commercial advancement with Un...